Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility

Baloxavir marboxil (BXM) was approved in 2018 for treating influenza A and B virus infections. It is a first-in-class inhibitor targeting the endonuclease activity of the virus polymerase acidic (PA) protein. Clinical trial data revealed that PA amino acid substitutions at residue 38 (I38T/F/M) redu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Proc Natl Acad Sci U S A
Hauptverfasser: Jones, Jeremy C., Pascua, Philippe Noriel Q., Fabrizio, Thomas P., Marathe, Bindumadhav M., Seiler, Patrick, Barman, Subrata, Webby, Richard J., Webster, Robert G., Govorkova, Elena A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: National Academy of Sciences 2020
Schlagworte:
Biological Sciences
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7165484/
https://ncbi.nlm.nih.gov/pubmed/32217734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1916825117
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge